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Synaptojanin 2, a novel Rac1 effector that regulates clathrin-
mediated endocytosis
Nicole Malecz*, Peter C. McCabe†‡, Caroline Spaargaren†§, Rong-Guo Qiu†#,
Ya-yu Chuang* and Marc Symons*†
The small GTPase Rac has been implicated in a wide
range of cellular processes, including the organization
of the actin cytoskeleton, transcriptional control and
endocytic vesicle trafficking [1–3]. The signaling
components that mediate these functions downstream
of Rac largely remain to be identified. In this study, we
have identified synaptojanin 2, a polyphosphoinositide
phosphatase as a novel Rac1 effector. Synaptojanin 2
directly and specifically interacts with Rac1 in a GTP-
dependent manner. Expression of constitutively active
Rac1 caused the translocation of synaptojanin 2 from
the cytoplasm to the plasma membrane. Both activated
Rac1 and a membrane-targeted version of
synaptojanin 2 inhibited endocytosis of the epidermal
growth factor (EGF) and transferrin receptors, a process
that is known to be dependent on polyphosphoinositide
lipids. Endocytosis of growth factor receptors is thought
to play an important role in the regulation of cell
proliferation. Thus, these results suggest that
synaptojanin 2 may mediate the inhibitory effect of
Rac1 on endocytosis and could contribute to Rac1-
mediated control of cell growth.
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Results and discussion
Isolation of a novel Rac1-interacting protein 
To isolate novel Rac1 effectors, we screened a HeLa cell
cDNA library using the yeast two-hybrid method and acti-
vated Rac1 (Rac1V12) as a bait. Two cDNA fragments were
obtained that encoded overlapping parts of the carboxy-ter-
minal domain of synaptojanin 2. Synaptojanin 2 is a novel,
ubiquitously expressed isoform of synaptojanin 1 [4,5], a
brain-specific phosphatidylinositol (PI) 5′-phosphatase that
has been implicated in synaptic vesicle recycling [6]. To
characterize the specificity of the interaction with the
carboxy-terminal synaptojanin 2 peptide (termed 2H28,
Figure 1d) obtained from the yeast two-hybrid screen, we
tested other Rho-family members that share some binding
partners with Rac1. We found that neither Cdc42 nor RhoA
interact with 2H28 (Figure 1a). Using several deletion con-
structs, we narrowed down the Rac-binding domain (RBD)
of 2H28 to 56 amino acids (Figure 1a). 
Characterization of human synaptojanin 2 as a Rac1
effector 
To determine whether synaptojanin 2 directly binds to
Rac1 in a nucleotide-dependent manner, we performed
in vitro binding assays. Bacterially expressed glutathione-
S-transferase (GST)-2H28-RBD fusion protein directly
bound to Rac1 purified from insect cells and preloaded with
GTPγS (Figure 1b). Some binding to GDP-bound Rac1
could also be detected; however, the affinity for Rac1–GTP,
as measured by enzyme-linked immunosorbent assay
(ELISA), was 5–10-fold higher than that for GDP (data not
shown). No binding to Cdc42–GTP could be detected. To
determine whether Rac1 associates with endogenous
synaptojanin 2 in vivo, we expressed constitutively acti-
vated, Myc-tagged RacL61 or Cdc42L61 in COS-1 cells,
immunoprecipitated the GTPases and performed western
blot analysis. Endogenous synaptojanin 2 strongly bound
to Rac1 but not to Cdc42 (Figure 1c). Thus, synaptojanin 2
fulfills all the essential criteria to establish it as a bona fide
Rac1 effector.
Human synaptojanin 2 is translocated to the plasma
membrane by Rac 1
Members of the synaptojanin family contain an amino-ter-
minal Sac1-like inositol polyphosphate phosphatase
domain, a central PI 5′-phosphatase domain and a variable
carboxy-terminal domain [4,5].
As Rac1 binds to the carboxy-terminal domain of synapto-
janin 2, we hypothesized that Rac1 may function to translo-
cate synaptojanin 2 to the plasma membrane. To
investigate this, we studied the localization of transfected
synaptojanin 2 in the presence or absence of co-transfected
Rac1V12 in A431 human carcinoma cells. Cells overex-
pressing synaptojanin 2 alone showed punctate cytoplasmic
staining (Figure 2a). When co-expressed with Rac1V12,
synaptojanin 2 relocalized with Rac1 to the plasma mem-
brane and was clearly visible in membrane ruffles
(Figure 2b,c). A carboxy-terminal truncation mutant of
synaptojanin 2, lacking the RBD, was no longer translocated
by Rac1 (see Supplementary material), underscoring the
importance of the interaction with Rac1 for translocation. 
Inhibition of endocytosis by synaptojanin 2 
We next addressed the question as to which Rac1-controlled
processes are mediated by synaptojanin 2. We focused on
two functions that are regulated by Rac and are thought to
be modulated by PI metabolism — clathrin-mediated
endocytosis and the organization of the actin cytoskeleton
[3]. Expression of RacV12 has been shown to inhibit
endocytosis of the transferrin receptor in HeLa cells [3].
We have extended these observations, using fluorescently
labelled EGF and showed that RacV12 also inhibits endo-
cytosis of the EGF receptor in A431 cells (Figure 3a,b).
To test the role of synaptojanin 2 in clathrin-mediated
endocytosis, we reasoned that Rac1 may localize synapto-
janin 2 to the plasma membrane and constructed a version
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Synaptojanin 2 is a novel Rac1 effector. (a) Yeast two-hybrid screen.
Plasmids encoding the 492 carboxy-terminal amino acids of
synaptojanin 2 (2H28), the amino-terminal half of 2H28 (2H28-N,
amino acids 1004–1213) or the RBD (2H28-RBD, amino acids
1142–1197), were co-transformed with plasmids containing activated
versions of the indicated Rho-family members and tested for growth
on medium lacking histidine (see Supplementary material for
additional details). (b) In vitro binding: GST–2H28-RBD fusion
protein bound to glutathione agarose was incubated with Glu–Glu-
tagged Rac1, preloaded with either GDP (lane 2) or GTPγS (lane 3),
or Glu–Glu-tagged Cdc42 preloaded with GTPγS (lane 4). As a
control, GST protein alone was incubated with Rac1–GTP (lane 1).
After binding and washing, proteins remaining bound to Rac1 were
detected by immunoblotting with anti-Glu–Glu monoclonal antibody.
(c) In vivo binding: COS-1 cells were transfected with pRK5-
Myc–RacL61 or pRK5-Myc-Cdc42L61. GTPases were
immunoprecipitated with an anti-Myc antibody and detected by
immunoblotting. Top panel: 6% polyacrylamide gel, synaptojanin 2
(SJ2) antiserum. Bottom panel: 10% polyacrylamide gel, anti-Myc
antibody. (d) Schematic drawing of the constructs used. 
Figure 2
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(c)
Rac1 translocates synaptojanin 2 to the plasma membrane. A431
cells were transfected with (a) either full-length synaptojanin 2 alone, or
(b,c) co-transfected with synaptojanin 2 and Rac1V12. Cells were
processed for indirect immunofluorescence using anti-T7 antibody to
visualize Rac1 (b) and anti-synaptojanin 2 antiserum to visualize
synaptojanin 2 (a,c). The scale bar represents 20 µm. 
of synaptojanin 2 that is constitutively membrane-targeted
in a Rac-independent fashion by fusing the central PI
5′-phosphatase domain to the CAAX-motif-containing
carboxyl terminus of K-ras. This construct (termed
PD–CAAX) localizes to the plasma membrane (Figure 3c).
Overexpression of PD–CAAX efficiently inhibited endo-
cytosis of the EGF receptor (Figure 3d). Overexpression
of synaptojanin 2 alone had no significant effect on endo-
cytosis (data not shown). This is probably due to the fact
that overexpressed synaptojanin 2 may not target effi-
ciently to the plasma membrane. 
To test whether the inhibitory effect of PD–CAAX depends
on its enzymatic activity, we constructed a phosphatase-
inactive version using site-directed mutagenesis of the
two conserved arginines (at positions 796 and 803) in the
PI 5′-phosphatase domain [7]. This recombinant protein
still targeted to the plasma membrane (Figure 3e), but no
longer inhibited endocytosis (Figure 3f). The PI 5′-phos-
phatase domain by itself, without a membrane-targeting
sequence, showed a similar cytoplasmic distribution to
full-length synaptojanin 2 (Figure 3g) and had no effect on
endocytosis either (Figure 3h). Thus, the inhibitory effect
of synaptojanin 2 on endocytosis requires its membrane
targeting. Identical results were obtained when the effects
of these constructs were tested on endocytosis of the
transferrin receptor (data not shown). We have also tested
whether Rac1 can modulate the lipid phosphatase activity
of synaptojanin 2 in vitro, using Rac1 and synaptojanin 2
purified respectively from insect cells and COS cells and
PI(3,4,5)P3 as a substrate, but thus far we have failed to
detect any effect of Rac1 on the phosphatase activity of
synaptojanin 2 (data not shown).
PI lipids play a prominent role in the regulation of endocy-
tosis. A number of different PI lipids bind the adaptor
protein complex AP-2, facilitating its self-assembly, and its
interaction with clathrin and peptides that contain endo-
cytic motifs [8]. PIs are also necessary for the activity of
the dynamin GTPase, which is essential for vesicle scis-
sion from the plasma membrane [9]. Given the strong
dependence of the endocytic machinery on PI(4,5)P2 [10],
a probable mechanism for the inhibitory effect of the
membrane-targeted PI 5′-phosphatase is the induction of
a decrease in PI(4,5)P2 levels. We therefore suggest that
Rac1 regulates endocytosis at least in part by targeting
synaptojanin 2 to the plasma membrane. 
Another Rac1-controlled function that is likely to involve
PI metabolism is the formation of lamellipodia. Activated
Rac is thought to regulate the dynamics of lamellipodia by
stimulating actin polymerization at the cell periphery and
the activity of a number of actin-binding proteins, includ-
ing capping and severing proteins, is known to be modu-
lated by PI lipids [11]. To investigate the potential role of
synaptojanin 2 in the regulation of actin dynamics, we
expressed PD–CAAX in A431 cells and examined its
effect on EGF-stimulated lamellipodia formation. At
expression levels where PD–CAAX strongly inhibited
endocytosis, however, no effect on the formation of lamel-
lipodia could be observed (Figure 4). Thus, it appears that
the integrity of the endocytic machinery may be much
more sensitive to a decrease in plasma membrane PI
content than lamellipodia formation. In addition, these
observations underline the specificity of the inhibitory
effect of PD–CAAX on endocytosis.
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Figure 3
Effects of Rac1 and synaptojanin 2 mutants on EGF receptor
endocytosis. A431 cells were transiently transfected on coverslips
with (a,b) Rac1-V12, (c,d) a membrane-targeted PI 5′-phosphatase
domain (PD–CAAX), (e,f) a membrane-targeted, phosphatase-inactive
PI 5′-phosphatase domain or (g,h) the central PI 5′-phosphatase
domain without a membrane localization sequence. After incubation
with rhodamine–EGF, cells were treated for indirect
immunofluorescence using anti-T7 antibody followed by FITC-
conjugated anti-mouse antibody to visualize Rac1 (a) or anti-Myc
antibody followed by FITC-anti-mouse antibody to visualize the
synaptojanin 2 proteins (c,e,g). The internalized rhodamine–EGF for
the respective constructs is shown in (b,d,f,h). Non-internalized
rhodamine–EGF was removed by acid washing. For each experiment
between 80 and 100 cells were evaluated. Inhibition of endocytosis
with Rac1 and the membrane-targeted PI 5′-phosphatase domain was
observed in all cases. The scale bars represent 20 µm. 
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Conclusions
We identify the PI phosphatase synaptojanin 2 as a novel
Rac1 effector. We show that Rac1 can translocate synapto-
janin 2 to the plasma membrane and that a membrane-tar-
geted version of synaptojanin 2 specifically inhibits
endocytosis. These results strongly suggest that synapto-
janin 2 mediates the inhibitory effect of Rac1 on endocyto-
sis. The endocytosis of growth factor receptors and their
subsequent targeting to lysosomes negatively regulates
growth factor signaling and inhibition of endocytosis has
been shown to enhance cell proliferation [12]. Rac has been
implicated in the regulation of cell proliferation [13] and it
will therefore be of interest to determine whether synapto-
janin 2 mediates the function of Rac1 in this process. 
Supplementary material
Supplementary material including methodolgical details and additional
figures is available at http://current-biology.com/supmat/supmatin.htm.
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Synaptojanin 2 does not inhibit lamellipodia formation. A431 cells in
the absence of serum were transiently transfected with
(a,b) PD–CAAX or (c) left untransfected. Cells were stimulated with
100 nM EGF for 3 min and processed for indirect
immunofluorescence. PD–CAAX was visualized by anti-Myc antibody
(a) and the actin cytoskeleton was stained by FITC–phalloidin (b,c). 
